2002
DOI: 10.1016/s1081-1206(10)61955-2
|View full text |Cite
|
Sign up to set email alerts
|

Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
35
0
2

Year Published

2005
2005
2018
2018

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(37 citation statements)
references
References 21 publications
0
35
0
2
Order By: Relevance
“…Although numerous clinical trials have established the efficacy of intranasal corticosteroids in adults and adolescents with PAR, fewer studies have evaluated the efficacy of these drugs in children <12 years of age [7][8][9][10][11][12], and none of these pediatric trials assessed efficacy for longer than 12 weeks.…”
Section: Introductionmentioning
confidence: 99%
“…Although numerous clinical trials have established the efficacy of intranasal corticosteroids in adults and adolescents with PAR, fewer studies have evaluated the efficacy of these drugs in children <12 years of age [7][8][9][10][11][12], and none of these pediatric trials assessed efficacy for longer than 12 weeks.…”
Section: Introductionmentioning
confidence: 99%
“…Inhaled glucocorticosteroid treatment represents an efficacious approach for allergic rhinitis [9][10][11][12] reducing the edema of nasal mucosa and the experimental influx of inflammatory cells in the nose of allergic patients [1]. Indeed, treatment with intranasal glucocorticosteroids reduces the swelling of the nasal mucosa, which leads to airflow obstruction, and decreases the numbers of Langerhans cells, mast cells, eosinophils and T-cells in the upper airways of patients with intermittent or persistent allergic rhinitis [1,[9][10][11][12].…”
Section: Introductionmentioning
confidence: 99%
“…Indeed, treatment with intranasal glucocorticosteroids reduces the swelling of the nasal mucosa, which leads to airflow obstruction, and decreases the numbers of Langerhans cells, mast cells, eosinophils and T-cells in the upper airways of patients with intermittent or persistent allergic rhinitis [1,[9][10][11][12].…”
Section: Introductionmentioning
confidence: 99%
“…In children and adults, randomized, double-blinded, placebo-controlled studies of BANS, FPNS, MFNS, and TANS have shown that the recommended once-daily starting doses of these INSs are well tolerated and are more effective than placebo in treating both SAR and PAR. [19][20][21][22][23][24][25][26] Head-to-head comparisons of INS sprays (single or multiple dosing) in adult patients (18 or more years of age) have found no consistent differences in efficacy among them for treatment of AR. 27 Similarly, the MURPHY 218 three head-to-head studies that have included pediatric patients have not found consistent differences between once-daily aqueous INS sprays.…”
Section: Comparative Efficacy Of Inssmentioning
confidence: 99%
“…The onset of effect of the INSs has not been formally studied in children; however, one placebo-controlled study by Fokkens et al 19 evaluating pediatric and adolescent patients with PAR (n ϭ 202 patients aged 6 to 16 years) found that patients treated with BANS 128 g once daily had significantly lower combined nasal symptom scores than placebo patients within 12 hours of treatment (p value not reported) and had significantly greater peak nasal inspiratory flow scores compared to placebo patients within 48 hours of treatment (p ϭ 0.015). In general, studies in adults (some of these studies included patients 12 years of age and older) suggest that significant improvements compared with placebo varies with the symptoms examined and ranges from 3 to 12 hours.…”
Section: Comparative Efficacy Of Inssmentioning
confidence: 99%